Awiqli (insulin icodec-abae)
Novo Nordisk (NVO)
ApprovedMar 26, 2026
Marketer take
The first of two once-weekly basal insulins approved in 2026, giving insulin marketers a new dosing-frequency message in primary care; Lilly's weekly Onswik followed in September.
- Sponsor company
- Novo Nordisk (NVO)
- Indication
- To improve glycemic control in adults with type 2 diabetes mellitus
- Therapeutic area
- Diabetes, Metabolic
- Event
- FDA approval
- Date
- Mar 26, 2026
- Status
- Approved
- Source
- FDA page
- Last verified
- Nov 15, 2026
Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?